Sophia Genetics entered a new stage of its global expansion with its over-subscribed series F round exceeding USD 110 million led by a major health-tech fund and followed by a strategic industry leader.
The series F round was led by aMoon, a leading health-tech and life science venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi group. The company also received the trust of prime financial institutions Credit Suisse and the Pictet group. Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo and Eurazeo Growth participated in the round, as well as newcomers Ace & Company and Famille C Invest.
Tavernier Tschanz acted as lead counsel to Sophia Genetics in this transaction. Tavernier Tschanz has been involved in all financing rounds of Sophia Genetics since its incorporation.